Long-term Study of TAK-875.
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Fasiglifam (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Takeda
- 27 Dec 2013 Status changed from recruiting to discontinued, as reported by a Takeda media release.
- 01 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Sep 2011 New source identified and integrated (ClinicalTrials.gov record NCT01433406)